TWi Biotechnology’s AC-201 patent for China

•   January 8,2015
•   LEAVE A COMMENT

World has witnessed the emergence of many chronic and non-curable disease in humans since the past decade. Researchers and scientists from all across the globe are striving to come up with better and effective treatments to cure various chronic blood disorders. However, the number of patients affected by blood diseases have been rising for example; patients with diabetes, blood cancer, anemia and other chronic blood disorders.

As a result of the increase in number of patients with blood diseases and disorders, the drugs market for same has witnessed a rapid growth in demand and revenue from all across the globe. Diabetes, anemia and other such blood disorder are the most common among a large chunk of population from almost all age groups. 

Blood disorders affect the red blood cells, white blood cells and platelets. Red blood cells help in carrying oxygen to the body tissues, whereas; white blood cells fights against infection in the body and platelets helps the blood to clot. Damage to any of the above could possibly become a life threat for the patient.

The report on “Blood Disease Drugs Markets in China,” would help the readers with extensive knowledge of the market dynamics and competitive structure of the blood disease drugs market in the Chinese region. 

TWi Biotechnology, Inc., a leading Chinese biopharmaceutical company, has recently received approval in China, for its AC-201 drug for the treatment of type II diabetes. The patent covers the various method of treatment for type II diabetes using the AC-201. 

President of TWi Biotechnology, Dr. Calvin C. Chen says, "We are very pleased with the allowance of patent application in China for AC-201, after the issuance of two patents from the USPTO (US Patent & Trademark Office) in June this year.  These new patents combined will provide TWi Biotechnology intellectual property protection for AC-201 in addressing unmet medical needs as an effective treatment for type II diabetes and hyperuricemia." 

Dr. Chen further adds, “Currently, China ranks first as the country with the most people with diabetes, estimated at a total of 98 million patients in the country in 2013.  We hope the drug candidate AC-201 will develop well in China and will bring benefits to the vast number of diabetes patients in China after it obtains drug approval.”